Cheryl Barton

The new framework will position the UK as an attractive prospect for new medicine manufacturers.

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

What impact will EMA’s decision to phase out COVID-19 regulatory flexibilities have on the pharma industry?

What implications will EMA’s recent regulatory reform have on pharma?

Competition in the organ-on-a-chip market increases as NETRI enters the arena.

Stepwise paediatric investigation plans aim to boost the development of medicines for children.

TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.

The European Human Medicines Directive and Regulation is due to be updated by the end of 2022, but what changes are on the cards?

A new unitary patent system is due to come into effect in Europe later on this year.

Pharma’s leveraging real-world evidence to drive product approval, reimbursement, and market access.

On 26 May 2022, the European Commission will roll-out the new in-vitro diagnostic regulation.

In January 2022, Europe started to implement EU-CTR, a new regulatory framework for clinical trials, but what does this mean for pharma clinical research?

Pharma’s interest in decentralized clinical trials (DCTs) increases as it helps to expand their geographical reach and racial diversity

DTx manufacturers are taking advantage of the new regulatory flexibility, afforded by the COVID-19 pandemic, to pilot new products and generate real-world evidence to support regulatory filing and reimbursement.